Coronavirus infectious diseases 2019 (COVID-19), a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a serious public health threat worldwide. So far, there are no drugs and vaccines whose efficacy has been well-proven. After the outbreak, there has been a massive search for anti-SARS-CoV-2 medications, focusing on approved drugs because repurposing approved drugs will take less time to reach clinical usage than new drugs. This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Infection, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, RBD, receptor-binding domain, Screening, repositioning, ACE2, angiotensin converting enzyme 2, RdRp, RNA-dependent RNA polymerase, TMPRSS2, transmembrane protease, serine 2, PLpro, papain-like protease, approved drug, Mpro, Main protease, COVID-19, coronavirus infectious diseases 2019, IC50, a half maximal inhibitory concentration,
【저자키워드】 COVID-19, SARS-CoV-2, Infection, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, RBD, receptor-binding domain, Screening, repositioning, ACE2, angiotensin converting enzyme 2, RdRp, RNA-dependent RNA polymerase, TMPRSS2, transmembrane protease, serine 2, PLpro, papain-like protease, approved drug, Mpro, Main protease, COVID-19, coronavirus infectious diseases 2019, IC50, a half maximal inhibitory concentration,